Core Insights - The company's total revenue for the current period is approximately 3.85 billion, a decrease from 4.17 billion in the same period last year, indicating a decline in overall revenue [1] Revenue Breakdown by Industry - Pharmaceutical manufacturing generated approximately 2.00 billion, accounting for 52.00% of total revenue, compared to 2.20 billion and 52.67% in the previous year [1] - Pharmaceutical commerce contributed around 1.78 billion, representing 46.18% of total revenue, up from 1.90 billion and 45.67% year-on-year [1] - Other segments accounted for 70.23 million, or 1.82% of total revenue, slightly increasing from 69.08 million and 1.66% [1] Revenue Breakdown by Product - Raw material sales were approximately 663.46 million, making up 17.22% of total revenue, compared to 667.44 million and 16.01% last year [1] - Formulation sales totaled around 1.32 billion, representing 34.17% of total revenue, down from 1.52 billion and 36.36% [1] - Other product sales accounted for about 1.87 billion, or 48.61% of total revenue, increasing from 1.99 billion and 47.63% [1] Revenue Breakdown by Region - Export revenue was approximately 608.20 million, representing 15.79% of total revenue, compared to 415.56 million and 9.97% in the previous year [1] - Domestic sales accounted for around 3.24 billion, or 84.21% of total revenue, down from 3.75 billion and 90.03% [1] Cell Therapy Product Development - The company has established a comprehensive technology platform and product transformation system for cell therapy products, including TCR-T, CAR-T, and SNK [1] - The company has developed over ten cell therapy products targeting KRAS mutations, EGFRvIII, Claudin18.2, among others, for treating advanced pancreatic cancer, colorectal cancer, gastric cancer, liver cancer, and glioblastoma [1]